Tapentadol IR + Oxycodone IR
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Substance Abuse Detection
Conditions
Substance Abuse Detection
Trial Timeline
Feb 1, 2010 → Feb 1, 2012
NCT ID
NCT01545778About Tapentadol IR + Oxycodone IR
Tapentadol IR + Oxycodone IR is a pre-clinical stage product being developed by Johnson & Johnson for Substance Abuse Detection. The current trial status is completed. This product is registered under clinical trial identifier NCT01545778. Target conditions include Substance Abuse Detection.
What happened to similar drugs?
1 of 1 similar drugs in Substance Abuse Detection were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01545778 | Pre-clinical | Completed |
Competing Products
5 competing products in Substance Abuse Detection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2 | 35 |
| Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] | Gilead Sciences | Pre-clinical | 22 |
| RDC-0313 + Buprenorphine + Placebo | Alkermes | Phase 1 | 26 |
| naltrexone for extended release injectable suspension | Alkermes | Approved | 40 |
| modafinil | Pacific Biosciences | Phase 2 | 21 |